HealthCourt ruling Affects United States

FDA sets March deadline to finish mifepristone safety review

Published 10h ago · Latest report 1h ago

AI summary40s readNeutral

The Food and Drug Administration will conclude its safety review of the abortion pill mifepristone in March.

The Food and Drug Administration informed a federal court that its safety review of the abortion pill mifepristone will wrap up in March. A federal judge in Louisiana ordered the update during an ongoing lawsuit challenging mail delivery rules for the medication. Reproductive rights opponents quickly criticized the timeline for delaying potential restrictions on the drug.

The lawsuitA federal judge in Louisiana ordered the Food and Drug Administration to provide updates on its safety study.
The disputeOpponents of abortion rights condemned the timeline for keeping the drug available by mail through next year.

Why it matters

Mifepristone remains a central battleground in American reproductive rights following legal challenges aimed at rolling back federal approval and distribution rules. The outcome of ongoing court battles will determine whether patients can continue receiving the medication by mail.

What outlets agree on

The Food and Drug Administration stated that its safety review of mifepristone will conclude in March following a court order from a federal judge in Louisiana.

Tune your feed

Reactions